期刊文献+

转染反义VEGF_(121) cDNA恢复K562细胞β1整合素的活化功能 被引量:1

Restoring β1 Integrin Activation Function in K562 Cells Transfected with Antisense VEGF_(121) cDNA
暂未订购
导出
摘要 为了探索血管内皮细胞生长因子 (VEGF)在K5 6 2细胞 β1整合素活化功能中的作用 ,利用转染正义 (S)、反义 (As)VEGF12 1cDNA及空载体 (V ,pcDNA3 )的不同K5 6 2细胞株 ,通过流式细胞术检测其粘附分子VLA 4(CD4 9d/CD2 9)和VLA 5 (CD4 9e/CD2 9)表达及 β1整合素的可活化性。结果显示 :K5 6 2 /V ,K5 6 2 /S和K5 6 2 /As细胞 β1整合素VLA 4 (CD4 9d/CD2 9)与VLA 5 (CD4 9e/CD2 9)的表达率均在 92 %以上 ,但经 β1整合素活化剂 8A2抗体激活后 ,K5 6 2 /As细胞可活化表位 9EG7表达率较K5 6 2 /V细胞明显提高 (75 .6± 10 .5vs 4 1.2± 2 .1% ,P <0 .0 1)。结论 :转染反义VEGF12 1cDNA能增加K5 6 2细胞 To investigate the effect of vascular endothelial growth factor (VEGF) on β1 integrin (VLA 4 and VLA 5) activation ability in K562 cells transfected with antisense VEGF121 cDNA, K562 cells were transfected with antisense (As), sense (S) and vector (V, pcDNA 3). Flow cytometry was used to evaluate the expression rate of VLA 4 (CD49d/CD29) and VLA 5 (CD49e/CD29) and β1 integrin activation ability in the transfected K562 cells. The results showed that the expression rates of VLA 4 and VLA 5 were more than 92% in the transfected K562 cells and there was no difference among the K562/V, K562/S and K562/As cells. However, β1 integrin activated 9EG7 expression rate in K562/As cells was higher than that in K562/V cells [(75.6±10.5)% vs (41.2±2.1)%, P<0.01)] after activation with β1 integrin activator 8A2. It is concluded that function of β1 integrin to be activated is restored in K562 cells transfected with antisense VEGF121 cDNA.
出处 《中国实验血液学杂志》 CAS CSCD 2003年第3期235-237,共3页 Journal of Experimental Hematology
基金 国家自然科学基金资助项目 编号 3 9970 3 14
关键词 K562细胞 血管内皮生长因子 βl整合素 慢性髓性白血病细胞系 K562 cell vascular endothelial growth factor β1 integrin chronic myeloid leukemia cell line
  • 相关文献

参考文献14

  • 1阮国瑞,刘艳荣,陈珊珊,秦亚溱,于弘,常艳,李金兰,付家瑜.自分泌VEGF对人慢性髓性白血病细胞系K562的作用[J].中国实验血液学杂志,2001,9(3):202-206. 被引量:10
  • 2阮国瑞,刘艳荣,陈珊珊,李金兰,秦亚溱,付家瑜,白任奎.成人慢性髓性白血病骨髓细胞血管内皮生长因子的表达[J].中国实验血液学杂志,2001,9(1):5-9. 被引量:7
  • 3白任奎,陈珊珊,刘艳荣,李金兰,付家瑜,秦亚溱,高辉,于泓.K562细胞与纤连蛋白粘附缺陷机制初步探讨[J].中华医学杂志,2000,80(6):469-471. 被引量:2
  • 4Ben-Neriah Y, Daley GD, Mes-Masson A-M, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 1986; 233(4760) :212 - 214.
  • 5Daley GQ, Van-Etten RA, Baltimore D. Induction of chronic mye-b- genous leuke- mia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 1990; 247(4944) : 824 - 830.
  • 6Oda T, Heaney C, Hagopian JR, et al. Crid is the major tyrosine phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem, 1994; 269:22925 - 22928.
  • 7Andoniou CE, Thien CB, Langdon WY. Tumor induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. EMBOJ, 1994; 13:4515-4523.
  • 8Shuai K, Halpern J, ten-Hoeve J, et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene, 1996; 13:247-254.
  • 9Verfaillie CM, Hurley R, Lundell BI, et al. Integrin-mediated regulation of hematopoiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Acta Haematol, 1997; 97: 40- 52.
  • 10Verfaillie CM, Hurley R, Zhao RC, et al. Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR-ABL positive clone? J Lab Clin Med, 1997; 129:584- 591.k

二级参考文献13

  • 1Bazzoni G,J Bio Chem,1998年,273卷,6670页
  • 2Presta LG, Chen H, O′Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.Cancer Res, 1997; 57:4593- 4599
  • 3Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res, 1996; 56:393 - 401
  • 4Veiga JP, Afonso H, Sallan SE, et al. Acute lymphoblastic leukemia cells and their bone marrow stroma collaborate to induce endothelial cell proliferation thereby promoting leuke-mia cell survival. Blood, 1998; 92(10, suppl 1) :511a
  • 5Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 1997; 89:1870-1875
  • 6Shami PJ, Hussong JW, Rodgers GM, et al. Evidence of increased angiogenesis in the bone marrow of patients with acute nonlymphocytic leukemia. Blood, 1998; 92 ( 10,suppl 1) :512a
  • 7Aguayo A, Kantarjian H, Talpaz M, et al. Increased angiogenesis in chronic leukemia and myelodysplastic syndromes. Blood, 1998; 92( 10, suppl 1 ): 607a
  • 8Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 1999; 94:3717 - 3721
  • 9Majka M, Kowalczyk D, Gee M, et al. Evidence that both human and murine bcr-abl+ cells stimulate vasculogenesis in vivo in matrigel implants: potential therapeutical implica-tions. Blood, 1999; 94(10, suppl 1):100a
  • 10董凡,许新,景乃禾,金由辛.反义寡核苷酸抑制肿瘤细胞表达VEGF的研究[J].肿瘤,1997,17(2):63-66. 被引量:28

共引文献14

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部